Last updated on June 2018

Administration of Kisspeptin to Subjects With Reproductive Disorders


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hypogonadism | Polycystic Ovary Syndrome | Hyperprolactinemia | GnRH Deficiency | Klinefelter's Syndrome | Kallmann's Syndrome
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

  1. Healthy Volunteers

All healthy volunteers will meet the following criteria:

History
  • history of normal puberty with respect to onset and pace,
  • no history of chronic disease,
  • no prescription medications for at least 2 months with the exception of seasonal allergy medications and hormone replacement therapy,
  • no illicit drug use,
  • no excessive alcohol consumption (< 10 drinks/week),
  • no history of a medication reaction requiring emergency medical care,
  • no difficulty with blood draws,
  • for women, not breastfeeding and not pregnant.

Physical examination:

  • BMI > 18.5 and < 30 kg/m2,
  • normal blood pressure, (systolic BP < 140 mm Hg, diastolic < 90 mm Hg). Laboratory studies: (per MGH reference ranges unless noted otherwise)
  • white blood cell, platelet counts, prolactin, and TSH between 90% of the lower limit and 110% of the upper limit of the reference range,
  • normal hemoglobin,
  • BUN, creatinine, AST, ALT not elevated,
  • normal levels of LH, FSH, and sex steroids (estradiol or testosterone).

Additional criteria based on subject population:

  1. Healthy Men (n=80, for 40 finishing the study) will be recruited who meet the above criteria and:
    History
    • age between 21 and 40 years,
    • normal erectile and ejaculatory function by report, no history of reproductive disorders (i.e. no history of cryptorchidism).

Physical examination:

testicular volume >15 ml by Prader orchidometer.

2. Healthy women (n=240, for 120 finishing the study, 40 each to be studied in the follicular, pre-ovulatory, and luteal phases of the menstrual cycle) will be recruited who meet the above criteria and:

History

age between 21 and 40 years,

  • menstrual cycles between 25 and 35 days in duration, at least 11 periods/year, with no more than 5 days variability in cycle duration,
  • no oral contraceptives for at least 2 months.

Physical examination:

no evidence for androgen excess (hirsutism or acne).

Laboratory studies:

negative serum hCG pregnancy test at the time of screening, (additional urine pregnancy test will be conducted prior to drug administration),

if to receive estradiol treatment as a part of this study, negative screening for Factor V Leiden.

3. Healthy postmenopausal women (n=20, for 10 finishing the study) will be recruited who meet the above criteria and:

History

age between 50 and 60 years,

  • no menstrual periods within the last year,
  • previous history of menstrual cycles between 25 and 35 days in duration, with no more than 5 days variability in cycle duration,
  • if applicable, able to undergo washout from hormone therapy.

Physical examination:

no evidence for androgen excess (hirsutism or acne).

Laboratory studies:

if to receive estradiol treatment as a part of this study, negative screening for Factor V Leiden.

B. Subjects with Reproductive Disorders

All subjects with reproductive disorders will meet the following criteria:

History

18 years or older,

all medical conditions stable and well controlled,

no prescription medications known to affect reproductive endocrine function for at least 2 months or for 5 half-lives of the drug (whichever is shorter) except for medications used to treat the subject's reproductive condition,

no history of a medication reaction requiring emergency medical care,

no illicit drug use,

no excessive alcohol consumption (<10 drinks/week),

for women, not breastfeeding and not pregnant,

if applicable, able to undergo appropriate washout from hormone therapy.

Physical Examination:

normal blood pressure, (systolic BP < 140 mm Hg, diastolic < 90 mm Hg).

Laboratory Studies:

white blood cell, platelet counts, and TSH between 90% of the lower limit and 110% of the upper limit of the reference range,

  • prolactin below 110% of the upper limit of the reference range with the exception of participants with hyperprolactinemia who by definition will have elevated levels of prolactin.
  • hemoglobin
  • women: no less than 0.5 gm/dL below the lower limit of the reference range for normal women,
  • men: on adequate testosterone replacement therapy: normal male reference range; off testosterone replacement therapy: no lower than 0.5 gm/dL below the lower limit of the reference range for normal women (> 11.5 gm/dL in our laboratory), as men with hypogonadism off treatment have low serum testosterone levels which causes hemoglobin concentrations to fall to the female range,
  • BUN, creatinine, AST, ALT not elevated,
  • for women, negative serum hCG pregnancy test at the time of screening (additional urine pregnancy test will be conducted prior to drug administration).

Additional criteria based on subject population:

  1. Men and women with hypogonadotropic hypogonadism (n= 120: 80 males, 40 females to have 40 males and 20 females complete the study). All subjects will have confirmed diagnosis by low sex steroids in the setting of low or inappropriately normal gonadotropins. If needed to verify clinical criteria, additional diagnostic labs and imaging tests may be performed including but not limited to: ferritin, prolactin, sex steroids, FSH, LH and brain MRI.
  2. Women with Polycystic Ovarian Syndrome (PCOS) (n=20, for 10 finishing the study) All subjects will have a confirmed diagnosis of PCOS as evidenced by 2 or more of the following: oligoamenorrhea, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology, and exclusion of identifiable conditions that would result in this pattern. If needed to verify clinical criteria, additional diagnostic labs may be drawn including but not limited to: 17-OHP, sex steroids, FSH, LH.
  3. Men and women with hyperprolactinemia (n=16: 8 males, 8 females to have 4 males and 4 females complete the study). All subjects will have confirmed diagnosis by elevated levels of prolactin measured via blood test and MRI imaging confirming no pituitary abnormality or a microprolactinoma (<10 mm). Patients with a macroprolactinoma will be excluded. We will enroll subjects when they first present with hyperprolactinemia prior to receiving medication or subjects being treated with the dopamine agonist bromocriptine only. We will ask subjects being treated with bromocriptine to complete a washout period prior to the kisspeptin administration visit(s). The washout period will last at least 2 weeks. We will perform a blood test prior to the kisspeptin administration visit(s) to confirm elevated levels of prolactin.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.